UTC Therapeutics Inc. is recruiting patients for a Phase 1 clinical trial testing UCMYM802, a circular-mRNA-encoded anti-mesothelin CAR-T cell therapy, for people with mesothelin-positive advanced solid tumors including mesothelioma.
The trial, designated NCT06256055, aims to enroll up to 24 participants. It is a China-based study, with sites managed directly by the sponsor.
About the Study
This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.
Treatment Approach
This trial uses genetically engineered T cells that target mesothelin on mesothelioma cells.
Key trial details:
- Phase: Phase 1
- Sponsor: UTC Therapeutics Inc.
- Enrollment target: 24
- Status: Recruiting
Why This Trial Matters
CAR-T cell therapy has revolutionized treatment for blood cancers, and researchers are working to adapt this approach for solid tumors like mesothelioma.
Study Locations
Contact the trial sponsor for information about participating sites.
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening